It was announced yesterday that late stage studies went well for Vivus’ hopeful erectile dysfunction treatment, Avanafil. The new drug application will be ready for completion by early 2011.
The results were promising. Out of those who attempted sexual intercourse 15 minutes after they took the drug, there was an 80% penetration success rate. 67% taking Avanafil had successful intercourse to completion without losing their erection.
No serious side effects were reported, only minor complaints such as headache, flushing and nasal congestion as with other Erectile Dysfunction treatments, such as Viagra and Cialis. There was only a 2.8% rate of discontinuation by patients.
The application will be filed to the FDA in the first half of 2011 and yet another oral PDE5 inhibitor might be added to the list of successful treatments available for Erectile Dysfunction. Avanafil’s advantage is in that works so fast, within 15 minutes or less. It is thought that Avanafil is more selective than other treatments thus decreasing the risk of side effects.